ロード中...
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
PI3K-AKT-mTOR and Ras-Raf-MEK-ERK are the most commonly altered oncogenic pathways in solid malignancies. There has been a lot of enthusiasm to develop inhibitors to these pathways for cancer therapy. Unfortunately, the antitumor activities of single-agent therapies have generally been disappointing...
保存先:
| 出版年: | Ther Adv Med Oncol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4406912/ https://ncbi.nlm.nih.gov/pubmed/26673580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834015571111 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|